In a study by Knox and colleagues the combination of the histone deacetylase inhibitor HDAC6i—which was previously shown to decrease the expression of PD-L1 [129]—with anti-PD-1 antibodies, decreased tumour growth in a mouse melanoma model by shifting the TME phenotype from ‘cold’ to ‘hot’. Here, PDCD1 is linked to melanoma.